Navigation Links
Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer

BUDAPEST, Hungary, June, 7, 2007--A pioneering nasal spray could stop thousands of patients with cancer from suffering unnecessary pain; it was reported today1 at the 10th Congress of the European Association for Palliative Care, Budapest, 7–9 June. The study investigated whether this first in class novel formulation could provide fast onset of pain relief and short duration of effect, mirroring the breakthrough pain often experienced by patients with cancer.

The majority of patients with cancer experience chronic pain during the course of their illness.2 However, patients with cancer can experience breakthrough pain despite adequate chronic background pain treatment.3 Breakthrough pain comes on very quickly, lasts for about 30 minutes on average, and can be very intense.2–4 The ideal treatment should mimic the typical breakthrough pain episode and provide tight control of the pain, i.e. fast but short-acting pain relief.

The trial comparing intranasally with intravenously administered fentanyl showed that pain relief in all patients was 6–8 minutes after intranasal administration.1 The duration of pain relief provided by both routes was essentially the same.1 The bioavailability of the intranasal administered fentanyl was 89%.1

Dr Lona Christrup of the University of Copenhagen, Denmark, explained ‘As a model for patients with cancer, we tested intranasal fentanyl to treat patients suffering pain after dental surgery.’ Dr Christrup also stated that ‘The intranasal fentanyl spray used in our study provided tight control of the pain meaning fast onset of action and relatively short duration of effect, making it a promising method for treating breakthrough cancer pain. This method of administration has the added advantage of being very easy to use, which is especially important for patients with cancer.’

These findings were discussed in the ‘Challenges in treating breakthrough pain’ satellite symposium, which examined the problems in treating and managing this debilitating condition. Breakthrough pain is a complex condition needing individualised patient management,5 and is a very widespread problem among patients with cancer.6 A drug with fast onset, short duration of action and ease of use was deemed to be the ideal treatment. Currently, oral morphine is the most frequently used treatment for breakthrough pain. However, oral morphine is far from ideal for patients with breakthrough cancer pain for two reasons. It takes about 30 minutes to have an effect, missing the majority of the breakthrough pain episode, and lasts for 4–6 hours, far longer than the breakthrough pain episode.

Commenting on the trial findings, Dr Andrew Davies, Consultant in Palliative Care, Royal Marsden Hospital said: ‘The results of this trial are particularly interesting in terms of the potential use of intranasal fentanyl to relieve breakthrough pain in patients with cancer. This is a unique type of pain, and so needs a unique form of treatment. Our research has shown that most patients are prescribed strong oral opioid analgesics, despite the fact that these are not the best choice of treatment. Greater attention needs to be given to the problem of breakthrough pain, and healthcare professionals need to be made aware of the general principles of management, and particularly the pros and cons of different forms of strong opioid analgesics.’

NOTES FOR EDITORS

A background document focusing on breakthrough cancer pain is available on request.

For more information about breakthrough pain please visit the breakthrough pain resource www.breakthroughpain.eu where also full details of all presentations from the ‘Challenges in treating breakthrough pain’ satellite symposium can be found.

About Nycomed

Nycomed is an international pharmaceutical group that provides products for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets.

The company is active within a range of therapeutic areas, including cardiology, gastroenterology, osteoporosis, respiratory, pain and tissue management. New products are sourced both from own research and from external partners. Operating throughout Europe and in fast-growing markets such as Latin America, Russia/CIS and the Asia-Pacific region Nycomed has a presence in about 50 markets worldwide.

Privately owned, the combined group had non-audited estimated annual sales of approximately €3.4 billion and an EBITDA of €933.4 million (2006 results). In connection with the acquisition of the ALTANA Pharma AG, effective 1 January 2007, Nycomed is relocating its group headquarters from Roskilde (Denmark) to Zurich (Switzerland) in June 2007.

For more information visit www.nycomed.com

For further information

Dr Susan Craib, Wells Healthcare
Phone: +44 [0]1892 511600
Mobile: +44 [0]7703 544 957

Germany:
Susanne Hof, Nycomed, Head of External Communications
Phone: +49 7531 84 30 59
Mobile: +49 151 55 00 26 65

References

1. Popper L, Christrup L. Breakthrough pain: a randomised trial comparing nasal and intravenous fentanyl in patients with p ost-operative pain. Presented at the 10th Congress of the European Association for Palliative Care, Budapest, Hungary, 7–9 June 2007

2. Gomez-Batiste X, Madrid F, Moreno F, Gracia A, Trelis J, Nabal M, Alcalde R, Planas J, Camell H. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. Journal of Pain and Symptom Management 2002;24:45–52

3. Zeppetella G O’Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. Journal of Pain and Symptom Management 2000;20:87–92

4. Portenoy R and Hagen NA. Breakthrough pain; definition, prevalence, and characteristics. Pain 1990;41:273–281

5. Davies A. The art of breakthrough pain treatment. Presented in Challenges in treating breakthrough pain satellite symposium at the 10th Congress of the European Association for Palliative Care, Budapest, Hungary, 7 June 2007

6. Kaasa S. Challenges in breakthrough pain treatment. Presented in Challenges in treating breakthrough pain satellite symposium at the 10th Congress of the European Association for Palliative Care, Budapest, Hungary, 7 June 2007


'"/>




Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... February 18, 2017 Marapharm (OTCQB: ... purchase a Medical Delivery Service with the specific and ... between qualified patients and caregivers. The delivery service is ... in the Coachella Valley, California . ... Angeles area to the West, population 19,000,000. ...
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, Musculoskeletal, ... to grow at a CAGR of 9.4% from 2017-2022 and CAGR ... a CAGR of 9.5% from 2017 to 2027. The market is ... ... you Read on to discover how you can exploit the ...
(Date:2/17/2017)... plc (NYSE, TASE: PRGO) today announced it has received final ... bitartrate and homatropine methylbromide oral solution (syrup), 5 mg/1.5 mg ... methylbromide oral solution (syrup), 5 mg/1.5 mg per 5 mL ... and children 6 years of age and older. Annual sales ... million.   ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... , ... Johns Hopkins All Children's Hospital celebrated a major milestone with the ... marked the halfway point of construction and lifting of the final beam on the ... a center for innovation aimed at finding new discoveries and treatments for childhood diseases. ...
(Date:2/19/2017)... (PRWEB) , ... February 19, 2017 , ... Braun Industries ... JEMS Conference & Exposition, the event will take place February 23-25, 2017 at the ... will be in Booth #909 with three new ambulances on display. ...
(Date:2/18/2017)... ... 2017 , ... Focused start-ups, not traditional health care organizations, ... the recent NEJM Catalyst Insights Report on the New Marketplace. , NEJM ... a qualified group of U.S. executives, clinical leaders, and clinicians at organizations directly ...
(Date:2/18/2017)... ... February 18, 2017 , ... A new ... and contact points to easily connect elderly veterans of America's armed forces to ... funding. It also conveys material on this year's increase in the Veterans Pension ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... brings its educational assistance management solution to the exhibit floor for the ... Orlando, Fla. , From Feb. 19–23, 2017, more than 40,000 healthcare industry ...
Breaking Medicine News(10 mins):